T cells, B cells and neutrophils are key mediators ... T cells, moreover, cause organ-transplant rejection. All three cell types require ITPKB for their development or function.

Skaggs Institute for Innovative Medicines, the drug discovery division of Scripps Research, announced today that the FDA has ...

The potential for cell and gene therapies is growing, offering groundbreaking treatments for rare genetic disorders and ...

Explore a high-throughput picodroplet-based method for CAR-T cell functional validation that enables rapid, single-cell ...

In March 2025, Juventas Cell Therapy Ltd. conducted a phase Ib/II trial to evaluate the safety and efficacy of CNCT19 ...

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...

Less than a year after purchasing private cell therapy company ImmPact Bio to help refresh its ailing CAR-T pipeline, ...